Question 1

What is Gyre Therapeutics, Inc. Common Stock's WACC?

Accepted Answer

Gyre Therapeutics, Inc. Common Stock (GYRE) has a Weighted Average Cost of Capital (WACC) of 6.47%. This is calculated using a Cost of Equity of 6.47% (via CAPM with a beta of 0.27) and a pre-tax Cost of Debt of 5.00%, with an equity weight of 100.00% in the capital structure.

Question 2

Is Gyre Therapeutics, Inc. Common Stock's WACC high or low?

Accepted Answer

Gyre Therapeutics, Inc. Common Stock's WACC of 6.47% is below the typical range of 8-12% for most companies, indicating relatively low cost of capital and lower risk. WACC is used as the discount rate in DCF valuations — a lower WACC results in higher present values of future cash flows.

Question 3

How is Gyre Therapeutics, Inc. Common Stock's WACC calculated?

Accepted Answer

Gyre Therapeutics, Inc. Common Stock's WACC is calculated using the formula: WACC = (E/V × Re) + (D/V × Rd × (1-T)). The Cost of Equity (Re) of 6.47% is derived from the CAPM model using a beta of 0.27. The pre-tax Cost of Debt (Rd) is 5.00%. The capital structure is 100.00% equity and 0.00% debt.

Gyre Therapeutics, Inc. Common Stock (GYRE) — WACC 分析

WACC 构成

解读

Gyre Therapeutics, Inc. Common Stock（GYRE）WACC：6.47%

WACC计算器

Gyre Therapeutics, Inc. Common Stock（GYRE） WACC 解读

GYRE 公司分析

GYRE DCF 估值

继续做同行对比